Evaluation of high-dose insulin/euglycemia therapy for suspected β-blocker or calcium channel blocker overdose following guideline implementation

Author(s):  
Rachel F Schult ◽  
Nicholas Nacca ◽  
Tori L Grannell ◽  
Rachel M Jorgensen ◽  
Nicole M Acquisto

Abstract Purpose High-dose insulin/euglycemia (HDIE) is targeted therapy for β-blocker and calcium channel blocker overdose. A guideline using concentrated insulin infusions (20 units/mL), aggressive monitoring, and supportive recommendations was implemented. We sought to evaluate safety before and after HDIE guideline implementation and describe the patient population, insulin doses, supplemental dextrose, vasopressor use, hospital and intensive care unit (ICU) lengths of stay, and mortality. Methods Retrospective review was performed of patients receiving HDIE before and after guideline implementation at an academic medical center and community hospital from March 2011 through December 2019. Information on patient and overdose demographics, ingestion data, vital signs, interventions, adverse events, and disposition was collected. Data are presented descriptively with comparisons using Mann-Whitney U analysis and Fisher’s exact tests. Results During the study period, 27 patients were treated with HDIE, 10 before guideline implementation (37%; mean [SD] initial insulin dose, 0.49 [0.35] units/kg/h; mean [SD] maximum insulin dose, 2.25 [3.29] units/kg/h; median [interquartile range] duration, 10 [5.5-18.75] hours) and 17 after guideline implementation (63%; mean [SD] initial insulin dose, 1.01 [0.34] units/kg/h; mean [SD] maximum insulin dose, 2.99 [5.05] unit/kg/h; median [interquartile range] duration, 16 [11.5-37] hours). Hypoglycemia, hypokalemia, and volume overload occurred in 80% vs 29% (P = 0.018), 40% vs 53% (P = 0.69), and 50% vs 65% (P = 0.69) of patients in the preguideline vs postguideline group, respectively. Most patients received an initial insulin bolus (85%; mean [SD], 70.3 [21.8] units, 0.9 [0.26] units/kg) and vasopressor infusion (85%). More postguideline patients received a dextrose infusion with a concentration of 20% or higher (93% vs 50%, P = 0.015). There were no differences in cardiac arrest, in-hospital mortality, or hospital or ICU length of stay between the groups. Conclusion Hypoglycemia was reduced using an HDIE guideline and concentrated insulin.

2020 ◽  
Vol 16 ◽  
Author(s):  
Seiji Umemoto ◽  
Toshio Ogihara ◽  
Masunori Matsuzaki ◽  
Hiromi Rakugi ◽  
Kazuyuki Shimada ◽  
...  

Background: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events) three benidipine (a calcium channel blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40–85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a β-blocker (n=1,089) or an additional angiotensin receptor blocker (ARB; n=1,110). A significantly higher incidence of hard cardiovascular composite endpoints and of fatal or non-fatal strokes was observed in the benidipine-β-blocker group compared to the benidipine-thiazide group. Objective and Methods: We further evaluated the treatment effects of the three benidipine-based regimens on vascular and renal events in a sub-analysis of the COPE patients. Results: A total of 10 vascular events (0.8 per 1,000 person-years) including one aortic dissection (0.1 per 1,000 person-years) and nine cases of peripheral artery disease (0.8 per 1,000 person-years) were documented, as was a total of seven renal events (0.6 per 1,000 person-years). No significant differences in vascular and renal events were revealed among the three treatment groups: vascular events p=0.92 renal events p=0.16 log-rank test. Conclusions: Blood pressure-lowering therapy with benidipine combined with an ARB, β-blocker, or thiazide was similarly effective in the prevention of vascular and renal events in hypertensive outpatients, although there is no enough these events to compare the difference in the three treatment groups.


2018 ◽  
Vol 36 (4) ◽  
pp. 736.e5-736.e6 ◽  
Author(s):  
Karan Seegobin ◽  
Satish Maharaj ◽  
Ansuya Deosaran ◽  
Pramod Reddy

2020 ◽  
Vol 49 (1) ◽  
pp. 193-193
Author(s):  
Mohammad Sallam ◽  
Divij Parsrija ◽  
Rozaleen Phaltas ◽  
Christine Koshel ◽  
Ritesh Korumilli ◽  
...  

2020 ◽  
Vol 13 (01) ◽  
pp. 1-11
Author(s):  
Noverio Tarukallo ◽  
Haerani Rasyid

Salah satu faktor yang memiliki risiko yang terkait dengan kejadian disfungsi seksual pada pria adalah obat anti-hipertensi. Obat anti-hipertensi yang memiliki efek menyebabkan disfungsi seksual pada pria termasuk; diuretik, Clonidine, dan β-blocker (kecuali nebivolol), tetapi ada beberapa obat anti-hipertensi yang memiliki efek netral, bahkan memiliki efek positif yang dalam hal ini dapat meningkatkan fungsi seksual pada pria. Obat anti-hipertensi yang memiliki efek netral pada fungsi seksual pria meliputi; Calcium Channel Blocker dan ACE-Inhibitor dan yang memiliki efek meningkatkan fungsi seksual pada pria termasuk; ARB dan β-blocker yaitu nebivolol. Penggunaan obat anti-hipertensi dapat mempengaruhi fungsi seksual pada pria melalui mekanisme yang berbeda. Obat anti-hipertensi seperti diuretik, β-blocker, dan clonidine dapat menyebabkan disfungsi seksual pada pria melalui mekanisme perubahan dalam aliran simpatis, efek pada kontraksi otot polos fisik, dan melalui pengaruh pada kadar hormon androgen. Angiotensin Receptor Blocker dan Nebivolol dapat meningkatkan fungsi seksual melalui mekanisme penghambatan pada Angiotensin II dan meningkatkan bioavailabilitas Nitric Oxide.


2018 ◽  
Vol 36 (10) ◽  
pp. 1817-1824 ◽  
Author(s):  
Jon B. Cole ◽  
Ann M. Arens ◽  
JoAn R. Laes ◽  
Lauren R. Klein ◽  
Stacey A. Bangh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document